Dadullah Faiz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dadullah Faiz has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
Abdullah Imtiaz
Wah Medical College, Wah Cantt, Pakistan
2 shared publicationsAdithya Chandran
Indira Gandhi Medical College & Research Institute, Pondicherry, India
2 shared publicationsAnirudh Govind
JIPMER, Puducherry, India
2 shared publications- Ashesh Das
KPC Medical College and Hospital, Kolkata, India
2 shared publications - Elena Alupei
Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
2 shared publications Faiza Khalid
Department of Microbiology, Sheikh Zayed Medical College, Rahim Yar Khan, Pakistan
2 shared publications
Latest Publications
- Open Access
- 24 October 2026
- Published by Springer Nature in Virology Journal
Lymphocytic choriomeningitis virus: an under-recognized arenaviral threat with important maternal–fetal implications
- 24 October 2026
- Published by Springer Nature in Virology Journal
Open AccessLymphocytic choriomeningitis virus: an under-recognized arenaviral threat with important maternal–fetal implications
- Open Access
- 9 October 2026
- Published by Springer Nature in AIDS Research and Therapy
Immune checkpoint inhibitors for African people living with HIV: T-cell exhaustion, endemic co-infections, and the oncology trial gap
- 9 October 2026
- Published by Springer Nature in AIDS Research and Therapy
Open AccessImmune checkpoint inhibitors for African people living with HIV: T-cell exhaustion, endemic co-infections, and the oncology trial gap
- Open Access
- 1 October 2026
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 19, 1-14
Phage Therapy as a Self—Replicating Strategy for Besieged Health Systems
Background: Active conflict zones and resource-limited health settings face compounding challenges from disrupted antibiotic supply chains concurrent with the proliferation of multidrug-resistant (MDR) and pan-drug-resistant (PDR) pathogens. In such settings, drug availability directly determines clinical outcomes. Methods: A narrative review of the literature was conducted in accordance with adapted SANRA (Scale for the Assessment of Narrative Review Articles) criteria, searching PubMed/MEDLINE, EMBASE, Cochrane Library, and grey literature sources for articles published between 1st January 2001 and 1st April 2026. Of 8003 records identified, 42 met inclusion criteria and were incorporated into this review Seminal pre-2001 works and non-English-language sources from Eastern European phage therapy programmes were deliberately included to mitigate geographic publication bias. Main Findings: Bacteriophages possess unique pharmacokinetic properties, including self-replication exclusively at infection sites, enabling pathogen clearance from a minimal dose burden. The Phage Support Ukraine (PhageSP UKR) initiative demonstrated rapid local phage isolation against circulating MDR and PDR Klebsiella pneumoniae strains from combat casualties, bypassing conventional pharmaceutical manufacturing chains. In a subset of strains, phage-driven evolutionary tradeoffs can compel ESKAPE pathogensto shed resistance plasmids, including NDM-1metallo-β-lactamase determinants, re-sensitizing the effected strains to existing antibiotics — a strain-specific phenomenon rather than a general clinical outcome These effects act synergistically with host immune defences. Decades of data from the Eliava Institute and growing compassionate use evidence provide a foundational safety profile. The PhagoBurn randomised trial found bacterial burden reduction to be significantly slower with phage therapy than standard of care, a result attributable to subtherapeutic dosing in a substantial proportion of participants; it does not establish efficacy but highlights dose-optimisation as a critical unmet need prior to wider deployment. Conclusion: Bacteriophage therapy represents a biologically rational and logistically feasible intervention for health systems under siege. While large-scale randomised controlled trial evidence remains limited, pragmatic deployment supported by compassionate use data and adaptive regulatory frameworks provides justification for clinical application against otherwise untreatable infections in conflict and resource-limited settings. Targeted investments in phage biobanking, rapid point-of-care production protocols, and harmonized international regulatory pathways are urgently needed.
- 1 October 2026
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 19, 1-14
Open AccessPhage Therapy as a Self—Replicating Strategy for Besieged Health Systems
Background: Active conflict zones and resource-limited health settings face compounding challenges from disrupted antibiotic supply chains concurrent with the proliferation of multidrug-resistant (MDR) and pan-drug-resistant (PDR) pathogens. In such settings, drug availability directly determines clinical outcomes. Methods: A narrative review of the literature was conducted in accordance with adapted SANRA (Scale for the Assessment of Narrative Review Articles) criteria, searching PubMed/MEDLINE, EMBASE, Cochrane Library, and grey literature sources for articles published between 1st January 2001 and 1st April 2026. Of 8003 records identified, 42 met inclusion criteria and were incorporated into this review Seminal pre-2001 works and non-English-language sources from Eastern European phage therapy programmes were deliberately included to mitigate geographic publication bias. Main Findings: Bacteriophages possess unique pharmacokinetic properties, including self-replication exclusively at infection sites, enabling pathogen clearance from a minimal dose burden. The Phage Support Ukraine (PhageSP UKR) initiative demonstrated rapid local phage isolation against circulating MDR and PDR Klebsiella pneumoniae strains from combat casualties, bypassing conventional pharmaceutical manufacturing chains. In a subset of strains, phage-driven evolutionary tradeoffs can compel ESKAPE pathogensto shed resistance plasmids, including NDM-1metallo-β-lactamase determinants, re-sensitizing the effected strains to existing antibiotics — a strain-specific phenomenon rather than a general clinical outcome These effects act synergistically with host immune defences. Decades of data from the Eliava Institute and growing compassionate use evidence provide a foundational safety profile. The PhagoBurn randomised trial found bacterial burden reduction to be significantly slower with phage therapy than standard of care, a result attributable to subtherapeutic dosing in a substantial proportion of participants; it does not establish efficacy but highlights dose-optimisation as a critical unmet need prior to wider deployment. Conclusion: Bacteriophage therapy represents a biologically rational and logistically feasible intervention for health systems under siege. While large-scale randomised controlled trial evidence remains limited, pragmatic deployment supported by compassionate use data and adaptive regulatory frameworks provides justification for clinical application against otherwise untreatable infections in conflict and resource-limited settings. Targeted investments in phage biobanking, rapid point-of-care production protocols, and harmonized international regulatory pathways are urgently needed.
- 23 September 2026
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 25 (2) , 262
Breast cancer and diabetes mellitus–related mortality among U.S. adults: a 25-year CDC WONDER analysis (1999–2023)
- 23 September 2026
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 25 (2) , 262
Breast cancer and diabetes mellitus–related mortality among U.S. adults: a 25-year CDC WONDER analysis (1999–2023)
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (16_suppl)
Impact of cooking-related household air pollution (HAP) on never-smoker NSCLC risk in women: Systematic review and meta-analysis.
e20690 Background: Among pollutants, exposure to cooking-related household air pollution (HAP) is a significant environmental health concern, particularly problematic for women who are non-smokers but still face a rising incidence of non-small cell lung cancer (NSCLC). However, globally, tobacco is the leading cause of cancers, but a substantial number of lung cancer cases have been reported among women, especially from low-income countries, who never smoked. Ultimately, our systematic review and meta-analysis focus on investigating the association between various cooking-related pollutants, such as cooking oil fumes and biomass fuel combustion, and risk for the development of NSCLC among these women. The pooled data will provide clarification of the impact of indoor smoking environmental pollutants on lung cancer etiology in never-smoking women. Methods: This systematic review and meta-analysis followed PRISMA guidelines and registered with PROSPERO. A total of 1901 articles were retrieved using databases including PubMed, Scopus, and EMBASE from inception to January 2026. Eligible studies evaluating the impact of exposure to cooking-related household air pollution (HAP) on the occurrence of non-small cell lung carcinoma among non-smoking adult women ≥18 years, compared with women unexposed to HAP were included. Data were analyzed using RevMan version 5.4 with a random-effects model to estimate pooled odd ratios (ORs) with 95% confidence intervals. A p-value < 0.05 was considered statistically significant. Results: Our systematic review and meta-analysis pooled results demonstrated a visible link between indoor pollution exposure and lung cancer. HAP exposure showed no significant association with lung cancer vs. healthy controls (OR: 0.66; 95% CI: 0.25-1.76, P = 0.41). Although limited by high heterogeneity (I2 = 99%), these results reflect variation in individuals across the globe. From the structural analysis of event sizes, we deduced that HAP exposure led to 1.51 times more chance of acquiring lung cancer (OR: 1.51; 95% CI: 1.25, 1.81; I2 = 20%; P < 0.0001). Our findings were verified from the reported HR: 2.04 (95% CI: 1.47, 2.82; I2 = 0%; P < 0.0001), indicating that exposed individuals had twice the chance of lung cancer being diagnosed. Conclusions: This systematic review and meta-analysis substantiates cooking-related household air pollution as an important etiologic factor in lung cancer among never-smoking women, implicating indoor combustion byproducts and supporting targeted public health interventions.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (16_suppl)
Impact of cooking-related household air pollution (HAP) on never-smoker NSCLC risk in women: Systematic review and meta-analysis.
e20690 Background: Among pollutants, exposure to cooking-related household air pollution (HAP) is a significant environmental health concern, particularly problematic for women who are non-smokers but still face a rising incidence of non-small cell lung cancer (NSCLC). However, globally, tobacco is the leading cause of cancers, but a substantial number of lung cancer cases have been reported among women, especially from low-income countries, who never smoked. Ultimately, our systematic review and meta-analysis focus on investigating the association between various cooking-related pollutants, such as cooking oil fumes and biomass fuel combustion, and risk for the development of NSCLC among these women. The pooled data will provide clarification of the impact of indoor smoking environmental pollutants on lung cancer etiology in never-smoking women. Methods: This systematic review and meta-analysis followed PRISMA guidelines and registered with PROSPERO. A total of 1901 articles were retrieved using databases including PubMed, Scopus, and EMBASE from inception to January 2026. Eligible studies evaluating the impact of exposure to cooking-related household air pollution (HAP) on the occurrence of non-small cell lung carcinoma among non-smoking adult women ≥18 years, compared with women unexposed to HAP were included. Data were analyzed using RevMan version 5.4 with a random-effects model to estimate pooled odd ratios (ORs) with 95% confidence intervals. A p-value < 0.05 was considered statistically significant. Results: Our systematic review and meta-analysis pooled results demonstrated a visible link between indoor pollution exposure and lung cancer. HAP exposure showed no significant association with lung cancer vs. healthy controls (OR: 0.66; 95% CI: 0.25-1.76, P = 0.41). Although limited by high heterogeneity (I2 = 99%), these results reflect variation in individuals across the globe. From the structural analysis of event sizes, we deduced that HAP exposure led to 1.51 times more chance of acquiring lung cancer (OR: 1.51; 95% CI: 1.25, 1.81; I2 = 20%; P < 0.0001). Our findings were verified from the reported HR: 2.04 (95% CI: 1.47, 2.82; I2 = 0%; P < 0.0001), indicating that exposed individuals had twice the chance of lung cancer being diagnosed. Conclusions: This systematic review and meta-analysis substantiates cooking-related household air pollution as an important etiologic factor in lung cancer among never-smoking women, implicating indoor combustion byproducts and supporting targeted public health interventions.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (16_suppl)
A systematic review and meta-analysis of artificial intelligence–assisted colon capsule endoscopy for colorectal polyp detection.
e15520 Background: Colorectal cancer remains a leading cause of cancer-related mortality worldwide, with early polyp detection crucial for prevention. Colon capsule endoscopy (CCE) offers a non-invasive alternative to traditional colonoscopy, but diagnostic accuracy is limited by the time-consuming image review and human error. Artificial intelligence (AI) has emerged as a promising tool to enhance CCE performance. This systematic review and meta-analysis aimed to evaluate the diagnostic accuracy of AI-assisted CCE for detecting colorectal polyps. Methods: We conducted a systematic review and diagnostic meta-analysis of studies evaluating AI-assisted CCE for colorectal polyp detection. Five studies published between 2020 and 2025 were included (Yamada 2020, Saraiva 2021, Gilabert 2022, Mascarenhas 2022, and Nadimi 2025). All employed retrospective designs using deep learning algorithms, primarily convolutional neural networks (CNNs), trained on CCE video frames. Primary outcomes were pooled sensitivity and specificity. Secondary outcomes included diagnostic accuracy, positive predictive value (PPV), negative predictive value (NPV), and area under the receiver operating characteristic curve (AUC). Random-effects models with the DerSimonian-Laird method were applied, and heterogeneity was assessed using the I² statistic. Results: Five studies comprising 3,897 polyp-positive frames were analyzed. The pooled sensitivity for AI-assisted CCE in detecting colorectal polyps was 93.44% (95% CI: 76.41%-98.43%), with high heterogeneity (I² = 98.1%). The pooled specificity was 94.63% (95% CI: 84.87%-98.22%, I² = 96.3%) based on four studies reporting this metric. Overall diagnostic accuracy was 94.97% (95% CI: 82.44%-98.70%, I² = 97.3%). Individual study sensitivities ranged from 79.0% (Yamada 2020) to 99.9% (Nadimi 2025), while specificities ranged from 79.2% (Saraiva 2021) to 99.4% (Nadimi 2025). Among studies reporting AUC values, performance ranged from 0.80 to 0.99. The high heterogeneity observed across all metrics suggests substantial variability in study populations, AI algorithms, and methodological approaches. Conclusions: AI-assisted CCE demonstrates excellent diagnostic performance for colorectal polyp detection, with pooled sensitivity and specificity both exceeding 93%. These findings suggest that AI integration can significantly enhance the diagnostic capabilities of CCE, potentially making it a viable alternative to conventional colonoscopy for colorectal cancer screening. High negative predictive values (86.8%-99.8%) indicate that AI-assisted CCE is effective at ruling out polyps when the test is negative, which is crucial for screening applications. Future research should focus on prospective validation studies and standardization of AI reporting to facilitate clinical implementation.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (16_suppl)
A systematic review and meta-analysis of artificial intelligence–assisted colon capsule endoscopy for colorectal polyp detection.
e15520 Background: Colorectal cancer remains a leading cause of cancer-related mortality worldwide, with early polyp detection crucial for prevention. Colon capsule endoscopy (CCE) offers a non-invasive alternative to traditional colonoscopy, but diagnostic accuracy is limited by the time-consuming image review and human error. Artificial intelligence (AI) has emerged as a promising tool to enhance CCE performance. This systematic review and meta-analysis aimed to evaluate the diagnostic accuracy of AI-assisted CCE for detecting colorectal polyps. Methods: We conducted a systematic review and diagnostic meta-analysis of studies evaluating AI-assisted CCE for colorectal polyp detection. Five studies published between 2020 and 2025 were included (Yamada 2020, Saraiva 2021, Gilabert 2022, Mascarenhas 2022, and Nadimi 2025). All employed retrospective designs using deep learning algorithms, primarily convolutional neural networks (CNNs), trained on CCE video frames. Primary outcomes were pooled sensitivity and specificity. Secondary outcomes included diagnostic accuracy, positive predictive value (PPV), negative predictive value (NPV), and area under the receiver operating characteristic curve (AUC). Random-effects models with the DerSimonian-Laird method were applied, and heterogeneity was assessed using the I² statistic. Results: Five studies comprising 3,897 polyp-positive frames were analyzed. The pooled sensitivity for AI-assisted CCE in detecting colorectal polyps was 93.44% (95% CI: 76.41%-98.43%), with high heterogeneity (I² = 98.1%). The pooled specificity was 94.63% (95% CI: 84.87%-98.22%, I² = 96.3%) based on four studies reporting this metric. Overall diagnostic accuracy was 94.97% (95% CI: 82.44%-98.70%, I² = 97.3%). Individual study sensitivities ranged from 79.0% (Yamada 2020) to 99.9% (Nadimi 2025), while specificities ranged from 79.2% (Saraiva 2021) to 99.4% (Nadimi 2025). Among studies reporting AUC values, performance ranged from 0.80 to 0.99. The high heterogeneity observed across all metrics suggests substantial variability in study populations, AI algorithms, and methodological approaches. Conclusions: AI-assisted CCE demonstrates excellent diagnostic performance for colorectal polyp detection, with pooled sensitivity and specificity both exceeding 93%. These findings suggest that AI integration can significantly enhance the diagnostic capabilities of CCE, potentially making it a viable alternative to conventional colonoscopy for colorectal cancer screening. High negative predictive values (86.8%-99.8%) indicate that AI-assisted CCE is effective at ruling out polyps when the test is negative, which is crucial for screening applications. Future research should focus on prospective validation studies and standardization of AI reporting to facilitate clinical implementation.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (16_suppl)
Effects of prophylactic fibrin glue on post-gastric ESD bleeding in gastric neoplasm: A meta-analysis of randomized controlled trials.
e16148 Background: Post-procedural bleeding remains a significant complication following gastric endoscopic submucosal dissection (ESD), occurring in up to 15% of cases. Fibrin glue has been proposed as a protective barrier to mitigate this risk. We conducted a meta-analysis of randomized controlled trials (RCTs) to synthesize current evidence regarding the efficacy of fibrin glue in preventing post-ESD bleeding. Methods: A systematic review identified three RCTs (Kim 2025, Lee 2023, Kataoka 2019) comparing fibrin glue application versus standard care in patients undergoing gastric ESD. A total of 636 patients were included (318 fibrin glue; 318 standard care). The primary outcome was overall post-ESD bleeding within 4 weeks. Secondary outcomes included acute ( < 24 hours) and delayed ( > 24 hours) bleeding. Pooled risk ratios (RR) were calculated using random-effects models. Results: The analysis revealed no significant reduction in overall post-ESD bleeding with fibrin glue compared to control (9.7% vs. 10.7%; RR 0.91, 95% CI 0.57–1.44). Heterogeneity for the primary outcome was negligible (I 2 = 0.0%), indicating highly consistent findings across studies. Furthermore, no significant differences were observed in secondary outcomes, including acute bleeding (RR 0.72, 95% CI 0.15–3.44) or delayed bleeding (RR 1.11, 95% CI 0.52–2.36). While acute bleeding rates were numerically lower in the intervention group (3.9% vs. 5.5%), this did not reach statistical significance. Conclusions: Based on high-quality evidence from recent RCTs, prophylactic fibrin glue application does not significantly reduce bleeding rates following gastric ESD. The data suggest that routine use of fibrin glue is unwarranted in the general patient population. Future research should pivot toward identifying specific high-risk subgroups that may derive benefit, rather than unselected prophylaxis.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (16_suppl)
Effects of prophylactic fibrin glue on post-gastric ESD bleeding in gastric neoplasm: A meta-analysis of randomized controlled trials.
e16148 Background: Post-procedural bleeding remains a significant complication following gastric endoscopic submucosal dissection (ESD), occurring in up to 15% of cases. Fibrin glue has been proposed as a protective barrier to mitigate this risk. We conducted a meta-analysis of randomized controlled trials (RCTs) to synthesize current evidence regarding the efficacy of fibrin glue in preventing post-ESD bleeding. Methods: A systematic review identified three RCTs (Kim 2025, Lee 2023, Kataoka 2019) comparing fibrin glue application versus standard care in patients undergoing gastric ESD. A total of 636 patients were included (318 fibrin glue; 318 standard care). The primary outcome was overall post-ESD bleeding within 4 weeks. Secondary outcomes included acute ( < 24 hours) and delayed ( > 24 hours) bleeding. Pooled risk ratios (RR) were calculated using random-effects models. Results: The analysis revealed no significant reduction in overall post-ESD bleeding with fibrin glue compared to control (9.7% vs. 10.7%; RR 0.91, 95% CI 0.57–1.44). Heterogeneity for the primary outcome was negligible (I 2 = 0.0%), indicating highly consistent findings across studies. Furthermore, no significant differences were observed in secondary outcomes, including acute bleeding (RR 0.72, 95% CI 0.15–3.44) or delayed bleeding (RR 1.11, 95% CI 0.52–2.36). While acute bleeding rates were numerically lower in the intervention group (3.9% vs. 5.5%), this did not reach statistical significance. Conclusions: Based on high-quality evidence from recent RCTs, prophylactic fibrin glue application does not significantly reduce bleeding rates following gastric ESD. The data suggest that routine use of fibrin glue is unwarranted in the general patient population. Future research should pivot toward identifying specific high-risk subgroups that may derive benefit, rather than unselected prophylaxis.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (16_suppl)
ABVD versus BEACOPP for front-line treatment of Hodgkin lymphoma: A systematic review and meta-analysis.
e19039 Background: Hodgkin lymphoma is a curable malignancy, the choice of frontline therapy for advanced-stage disease remains debated. ABVD has been the backbone of treatment for decades because of its reliable efficacy and lower long-term toxicity, while escalated BEACOPP was introduced to improve disease control. Randomized trials show better progression-free survival with BEACOPP but no clear overall survival benefit. BEACOPP carries higher rates of acute toxicity, infertility, and secondary malignancies particularly relevant given patients' young age and long life expectancy. Interpretation of existing literature is limited by differences in study design, patient selection, follow-up duration, and outcome reporting, so many individual trials are underpowered. A systematic review and meta-analysis is needed to define balance between efficacy and toxicity in advanced Hodgkin lymphoma. Methods: A total of 2858 records were retrieved from PubMed, Embase, Scopus, ScienceDirect, and the Cochrane Library from inception January 2026. Eligible randomized controlled trials and comparative observational studies of frontline BEACOPP (standard/escalated) vs ABVD in classical Hodgkin lymphoma reporting overall survival (OS) and progression-free/event-free survival (PFS/EFS), while secondary outcomes included complete or objective response, treatment-related toxicity (including grade 3–4 adverse events), secondary malignancies, and treatment discontinuation due to adverse events, and health-related. Pooled analyses used RevMan random-effects models (pResults: Eight studies (n = 5187) assessed the effectiveness of BEACOPP compared to ABVD in patients with classical Hodgkin lymphoma receiving front-line systemic therapy. BEACOPP showed an 18% reduction in the risk of mortality (HR 0.82; 95% CI 0.48–1.41; p = 0.48) and a 38% reduction in the risk of progression (HR 0.62; 95% CI 0.45–0.85; p = 0.003), with moderate heterogeneity (I² = 55%). However, no significant differences were observed in complete response rate (RR 0.99; 95% CI 0.89–1.10; p = 0.82) or overall response rate (RR 1.03; 95% CI 0.95–1.11; p = 0.51) with heterogeneity (I² = 51% and 23%, respectively). BEACOPP was associated with a significantly higher risk of serious adverse events (RR 4.60; 95% CI 2.37–8.93; p = 0.04) and a higher risk of secondary malignancies (RR 1.30; 95% CI 0.47–3.58; p = 0.61), both reported with moderate heterogeneity (I² = 65% and 71%). Additionally, BEACOPP showed a non-significant reduction in the risk of event occurrence (HR 0.36; 95% CI 0.07–1.93; p = 0.23), though this result was limited by high heterogeneity (I² = 97%). Conclusions: BEACOPP improved progression free survival as compared to ABVD but did not significantly improve overall survival and was associated with significantly greater toxicity. This efficacy toxicity trade off must be put into close consideration with regimen choice.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (16_suppl)
ABVD versus BEACOPP for front-line treatment of Hodgkin lymphoma: A systematic review and meta-analysis.
e19039 Background: Hodgkin lymphoma is a curable malignancy, the choice of frontline therapy for advanced-stage disease remains debated. ABVD has been the backbone of treatment for decades because of its reliable efficacy and lower long-term toxicity, while escalated BEACOPP was introduced to improve disease control. Randomized trials show better progression-free survival with BEACOPP but no clear overall survival benefit. BEACOPP carries higher rates of acute toxicity, infertility, and secondary malignancies particularly relevant given patients' young age and long life expectancy. Interpretation of existing literature is limited by differences in study design, patient selection, follow-up duration, and outcome reporting, so many individual trials are underpowered. A systematic review and meta-analysis is needed to define balance between efficacy and toxicity in advanced Hodgkin lymphoma. Methods: A total of 2858 records were retrieved from PubMed, Embase, Scopus, ScienceDirect, and the Cochrane Library from inception January 2026. Eligible randomized controlled trials and comparative observational studies of frontline BEACOPP (standard/escalated) vs ABVD in classical Hodgkin lymphoma reporting overall survival (OS) and progression-free/event-free survival (PFS/EFS), while secondary outcomes included complete or objective response, treatment-related toxicity (including grade 3–4 adverse events), secondary malignancies, and treatment discontinuation due to adverse events, and health-related. Pooled analyses used RevMan random-effects models (pResults: Eight studies (n = 5187) assessed the effectiveness of BEACOPP compared to ABVD in patients with classical Hodgkin lymphoma receiving front-line systemic therapy. BEACOPP showed an 18% reduction in the risk of mortality (HR 0.82; 95% CI 0.48–1.41; p = 0.48) and a 38% reduction in the risk of progression (HR 0.62; 95% CI 0.45–0.85; p = 0.003), with moderate heterogeneity (I² = 55%). However, no significant differences were observed in complete response rate (RR 0.99; 95% CI 0.89–1.10; p = 0.82) or overall response rate (RR 1.03; 95% CI 0.95–1.11; p = 0.51) with heterogeneity (I² = 51% and 23%, respectively). BEACOPP was associated with a significantly higher risk of serious adverse events (RR 4.60; 95% CI 2.37–8.93; p = 0.04) and a higher risk of secondary malignancies (RR 1.30; 95% CI 0.47–3.58; p = 0.61), both reported with moderate heterogeneity (I² = 65% and 71%). Additionally, BEACOPP showed a non-significant reduction in the risk of event occurrence (HR 0.36; 95% CI 0.07–1.93; p = 0.23), though this result was limited by high heterogeneity (I² = 97%). Conclusions: BEACOPP improved progression free survival as compared to ABVD but did not significantly improve overall survival and was associated with significantly greater toxicity. This efficacy toxicity trade off must be put into close consideration with regimen choice.
- Open Access
- 31 May 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (6) , e72829
Peripartum Cardiomyopathy Presenting With Severe Biventricular Dysfunction, Valvular Regurgitation, and Familial Predisposition: A Case Report
Peripartum cardiomyopathy (PPCM) is defined as the onset of left ventricular systolic dysfunction either during pregnancy or up to 5 months after delivery, without any other known cause of heart failure. The exact pathogenesis of this disease is unknown, and its prognosis remains poorly understood. We present a case of a 27‐year‐old woman presenting at 37 + 3 weeks of gestation, with reduced ejection fraction, biventricular systolic dysfunction and dilation, and valvular regurgitation. She was managed with medications slightly different from guideline‐mediated standard therapy. The unique and most crucial detail of this case is that it showed a close family history of PPCM, as the patient's older sister had also died of the same cause. Learning objectives: genetic and familial risk of developing peripartum cardiomyopathy.
- 31 May 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (6) , e72829
Open AccessPeripartum Cardiomyopathy Presenting With Severe Biventricular Dysfunction, Valvular Regurgitation, and Familial Predisposition: A Case Report
Peripartum cardiomyopathy (PPCM) is defined as the onset of left ventricular systolic dysfunction either during pregnancy or up to 5 months after delivery, without any other known cause of heart failure. The exact pathogenesis of this disease is unknown, and its prognosis remains poorly understood. We present a case of a 27‐year‐old woman presenting at 37 + 3 weeks of gestation, with reduced ejection fraction, biventricular systolic dysfunction and dilation, and valvular regurgitation. She was managed with medications slightly different from guideline‐mediated standard therapy. The unique and most crucial detail of this case is that it showed a close family history of PPCM, as the patient's older sister had also died of the same cause. Learning objectives: genetic and familial risk of developing peripartum cardiomyopathy.